ERBB2 and breast cancer: Given the substantial inconsistency of these results, especially when considering advanced HER2+ BC, no definitive conclusions can be drawn on the clinical relevance of the evaluation of immune infiltrates in patients with advanced disease receiving chemotherapy and/or HER2 blockade.